Anti-TNF alfa therapy in ankylosing spondylitis.

Authors

  • Ana Rita Cravo Serviço de Reumatologia, Hospital Garcia de Orta, Almada.
  • Viviana Tavares
  • José Canas Da Silva

DOI:

https://doi.org/10.20344/amp.916

Abstract

Ankylosing spondylitis (AS) is an inflammatory chronic disease that affects young males and in more than 90% of cases is associated with HLA B27 antigen. Therapeutic options for those patients with spondyloarthropathies have been limited during the last decades. Infliximab and etanercept are both approved for the treatment of patients with active disease that does not respond to conventional therapies. Anti-TNF therapy is very effective in AS, and eventually can be more effective than in rheumatoid arthritis. In 2003 Assessments in Ankylosing Spondylitis Group (ASAS) published international recommendations about the use of these agents in AS, which can be used as guidance in taking decisions and elaborating guidelines. To define their utilization it is necessary more studies about efficacy, toxicity and about ways of use.

Downloads

Download data is not yet available.

How to Cite

1.
Cravo AR, Tavares V, Da Silva JC. Anti-TNF alfa therapy in ankylosing spondylitis. Acta Med Port [Internet]. 2006 Aug. 18 [cited 2022 Dec. 10];19(2):141-50. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/916

Issue

Section

Arquivo Histórico